Recent insights into the mode of action of memantine and ketamine
Identifieur interne : 004210 ( Ncbi/Merge ); précédent : 004209; suivant : 004211Recent insights into the mode of action of memantine and ketamine
Auteurs : Jon W. Johnson ; Nathan G. Glasgow ; Nadezhda V. PovyshevaSource :
- Current opinion in pharmacology [ 1471-4892 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Récepteurs du N-méthyl-D-aspartate.
- pharmacologie : Antagonistes des acides aminés excitateurs, Kétamine, Mémantine.
- Animaux, Conception de médicament, Humains, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Receptors, N-Methyl-D-Aspartate.
- chemical , pharmacology : Excitatory Amino Acid Antagonists, Ketamine, Memantine.
- Animals, Drug Design, Humans, Molecular Targeted Therapy.
Abstract
The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize
Url:
DOI: 10.1016/j.coph.2014.11.006
PubMed: 25462293
PubMed Central: 4318755
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000F95
- to stream Pmc, to step Curation: 000F70
- to stream Pmc, to step Checkpoint: 000800
- to stream PubMed, to step Corpus: 000714
- to stream PubMed, to step Curation: 000714
- to stream PubMed, to step Checkpoint: 000714
Links to Exploration step
PMC:4318755Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25462293</idno>
<idno type="pmc">4318755</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318755</idno>
<idno type="RBID">PMC:4318755</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000F95</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F95</idno>
<idno type="wicri:Area/Pmc/Curation">000F70</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F70</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000800</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000800</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000714</idno>
<idno type="wicri:Area/PubMed/Curation">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000714</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000714</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000714</idno>
<idno type="wicri:Area/Ncbi/Merge">004210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="ISSN">1471-4892</idno>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Humans</term>
<term>Ketamine (pharmacology)</term>
<term>Memantine (pharmacology)</term>
<term>Molecular Targeted Therapy</term>
<term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antagonistes des acides aminés excitateurs (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Kétamine (pharmacologie)</term>
<term>Mémantine (pharmacologie)</term>
<term>Récepteurs du N-méthyl-D-aspartate (antagonistes et inhibiteurs)</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Ketamine</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs du N-méthyl-D-aspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des acides aminés excitateurs</term>
<term>Kétamine</term>
<term>Mémantine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize <italic>N</italic>
-methyl-<sc>d</sc>
-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</p>
</div>
</front>
</TEI>
<double pmid="25462293"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25462293</idno>
<idno type="pmc">4318755</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318755</idno>
<idno type="RBID">PMC:4318755</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000F95</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F95</idno>
<idno type="wicri:Area/Pmc/Curation">000F70</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F70</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000800</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000800</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Recent insights into the mode of action of memantine and ketamine</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W." last="Johnson">Jon W. Johnson</name>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G." last="Glasgow">Nathan G. Glasgow</name>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V." last="Povysheva">Nadezhda V. Povysheva</name>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="ISSN">1471-4892</idno>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize <italic>N</italic>
-methyl-<sc>d</sc>
-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine.</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W" last="Johnson">Jon W. Johnson</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: jjohnson@pitt.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G" last="Glasgow">Nathan G. Glasgow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V" last="Povysheva">Nadezhda V. Povysheva</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25462293</idno>
<idno type="pmid">25462293</idno>
<idno type="doi">10.1016/j.coph.2014.11.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000714</idno>
<idno type="wicri:Area/PubMed/Curation">000714</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000714</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000714</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000714</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Recent insights into the mode of action of memantine and ketamine.</title>
<author><name sortKey="Johnson, Jon W" sort="Johnson, Jon W" uniqKey="Johnson J" first="Jon W" last="Johnson">Jon W. Johnson</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA. Electronic address: jjohnson@pitt.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Glasgow, Nathan G" sort="Glasgow, Nathan G" uniqKey="Glasgow N" first="Nathan G" last="Glasgow">Nathan G. Glasgow</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Povysheva, Nadezhda V" sort="Povysheva, Nadezhda V" uniqKey="Povysheva N" first="Nadezhda V" last="Povysheva">Nadezhda V. Povysheva</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Current opinion in pharmacology</title>
<idno type="eISSN">1471-4973</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Humans</term>
<term>Ketamine (pharmacology)</term>
<term>Memantine (pharmacology)</term>
<term>Molecular Targeted Therapy</term>
<term>Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antagonistes des acides aminés excitateurs (pharmacologie)</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Kétamine (pharmacologie)</term>
<term>Mémantine (pharmacologie)</term>
<term>Récepteurs du N-méthyl-D-aspartate (antagonistes et inhibiteurs)</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Ketamine</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs du N-méthyl-D-aspartate</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des acides aminés excitateurs</term>
<term>Kétamine</term>
<term>Mémantine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Thérapie moléculaire ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs. Both memantine and ketamine antagonize N-methyl-D-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel. Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent. Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects. Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Amérique |area= PittsburghV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:4318755 |texte= Recent insights into the mode of action of memantine and ketamine }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25462293" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a PittsburghV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |